LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced that its mobile healthcare application has entered the final stage of development. The company is completing testing, optimization, and deployment preparations before submitting the app for distribution on the Apple App Store and Google Play. Management expects the application to become available within the coming weeks, subject to platform review and technical requirements.
This milestone represents a transition from development to public availability, providing users with a primary mobile access point to the LataMed AI digital healthcare ecosystem. The app is designed to offer a convenient interface for accessing supported healthcare services, digital tools, and additional functionality as the platform expands. The development team is currently focused on final technical testing, interface optimization, platform compatibility, and deployment-related preparations.
Once launched, the application is expected to provide a scalable mobile foundation for introducing new healthcare-related features over time. Potential functionality includes patient-facing tools, healthcare-provider interaction, digital communications, access to medical and wellness information, healthcare-service coordination, and other features aimed at creating a more connected healthcare experience. The company emphasizes that mobile accessibility is crucial in Latin America, where smartphones are often the primary means of accessing digital services.
By making the platform available through both major app marketplaces, LataMed AI intends to offer users a direct and accessible way to engage with its healthcare ecosystem. The application also supports the company's long-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, and other participants in a more integrated digital healthcare environment. LataMed AI continues to develop its AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, as part of its broader healthcare strategy.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, “Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI. Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes.” He added, “Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools.”
The anticipated release is another step in moving LataMed AI's technology from development to user-facing digital healthcare infrastructure. After the initial launch, the company will evaluate additional functionality, platform integrations, and user-facing tools for future versions. Updates on submission, availability, and functionality will be provided as milestones are completed.
For more information, visit https://latamed.ai, follow the company's official social media channels, or review SEC filings at www.sec.gov.
